Adma Biologics (ADMA) EPS (Weighted Average and Diluted) (2020 - 2025)
Adma Biologics (ADMA) reported EPS (Weighted Average and Diluted) of $0.2 for Q4 2025, down 56.52% on a YoY basis from $0.46 in Q4 2024, and up 33.33% quarter-over-quarter from $0.15 in Q3 2025.
Adma Biologics (ADMA) EPS (Weighted Average and Diluted) (2020 - 2025) Analysis & Trends
Adma Biologics has reported EPS (Weighted Average and Diluted) for 6 years, with the latest figure at $0.2 in Q4 2025.
- For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) fell 56.52% year-over-year to $0.2; the trailing twelve-month figure through Dec 2025 stood at $0.6 (down 26.83% YoY), and the FY2025 full-year result was $0.6, down 25.93% from the prior year.
- EPS (Weighted Average and Diluted) for Q4 2025 stood at $0.2, up from $0.15 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $0.46 in Q4 2024, with the low at -$0.16 in Q1 2021.
- Historically, EPS (Weighted Average and Diluted) has averaged $0.02 across 5 years, with a median of -$0.03 in 2023.
- Annual changes were most pronounced in 2024 — EPS (Weighted Average and Diluted) surged 1400.0% — and 2025, when it slumped 56.52%.
- Adma Biologics' EPS (Weighted Average and Diluted) stood at -$0.07 in 2021, then advanced by 14.29% to -$0.06 in 2022, then plunged by 33.33% to -$0.08 in 2023, then surged by 675.0% to $0.46 in 2024, then tumbled by 56.52% to $0.2 in 2025.
- The last three EPS (Weighted Average and Diluted) figures came in at $0.2 (Q4 2025), $0.15 (Q3 2025), and $0.14 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Adma Biologics | 1.98 Bn | 1.89 Bn | 88.82 Mn | 0.20 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.20 |
| Sep 30, 2025 | 0.15 |
| Jun 30, 2025 | 0.14 |
| Mar 31, 2025 | 0.11 |
| Dec 31, 2024 | 0.46 |
| Sep 30, 2024 | 0.15 |
| Jun 30, 2024 | 0.13 |
| Mar 31, 2024 | 0.08 |
| Dec 31, 2023 | -0.08 |
| Sep 30, 2023 | 0.01 |
| Jun 30, 2023 | -0.03 |
| Mar 31, 2023 | -0.03 |
| Dec 31, 2022 | -0.06 |
| Sep 30, 2022 | -0.08 |
| Jun 30, 2022 | -0.07 |
| Mar 31, 2022 | -0.13 |
| Dec 31, 2021 | -0.07 |
| Sep 30, 2021 | -0.13 |
| Jun 30, 2021 | -0.15 |
| Mar 31, 2021 | -0.16 |